PriceTargets.com logo

Eli Lilly and Company - LLY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $1,002.22
  • Forecasted Upside: 30.54%
  • Number of Analysts: 21
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 17 Buy Ratings
  • 0 Strong Buy Ratings
$767.76 As of 12/20/2024 06:45 PM ET
▲ +10.22 (1.35%)

This chart shows the closing price for LLY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eli Lilly and Company Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LLY

Analyst Price Target is $1,002.22
▲ +30.54% Upside Potential
This price target is based on 21 analysts offering 12 month price targets for Eli Lilly and Company in the last 3 months. The average price target is $1,002.22, with a high forecast of $1,250.00 and a low forecast of $723.00. The average price target represents a 30.54% upside from the last price of $767.76.

This chart shows the closing price for LLY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 21 polled investment analysts is to moderate buy stock in Eli Lilly and Company. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 19 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 16 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 16 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 16 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 16 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/10/2024Bank of AmericaReiterated RatingBuy$997.00
11/15/2024Wolfe ResearchInitiated CoverageOutperform$1,000.00
11/4/2024Redburn AtlanticUpgradeHold
11/4/2024Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$1,025.00 ➝ $1,015.00
10/31/2024BarclaysLower TargetOverweight ➝ Overweight$1,025.00 ➝ $975.00
10/31/2024Bank of AmericaLower TargetBuy ➝ Buy$1,150.00 ➝ $1,100.00
10/25/2024CitigroupBoost TargetBuy ➝ Buy$1,060.00 ➝ $1,250.00
10/17/2024Sanford C. BernsteinInitiated CoverageOutperform$1,100.00
10/10/2024Truist FinancialBoost TargetBuy ➝ Buy$1,000.00 ➝ $1,033.00
10/3/2024Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Buy$1,025.00 ➝ $1,025.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
9/13/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$1,050.00 ➝ $1,100.00
9/13/2024CitigroupInitiated CoverageBuy ➝ Buy$1,060.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
9/5/2024Evercore ISIUpgradeHold
8/27/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$1,106.00 ➝ $1,106.00
8/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
8/16/2024GuggenheimBoost TargetBuy ➝ Buy$884.00 ➝ $1,030.00
8/14/2024Berenberg BankBoost TargetBuy ➝ Buy$1,000.00 ➝ $1,050.00
8/12/2024Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$725.00 ➝ $1,025.00
8/9/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$875.00 ➝ $1,000.00
8/9/2024Bank of AmericaBoost TargetBuy ➝ Buy$1,000.00 ➝ $1,125.00
8/9/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$1,001.00 ➝ $1,101.00
8/5/2024GuggenheimBoost TargetBuy ➝ Buy$855.00 ➝ $884.00
8/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
7/24/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
7/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
7/11/2024Berenberg BankBoost TargetBuy ➝ Buy$850.00 ➝ $1,000.00
7/11/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$900.00 ➝ $1,000.00
7/10/2024BarclaysBoost TargetOverweight ➝ Overweight$913.00 ➝ $1,025.00
7/5/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$1,023.00 ➝ $1,023.00
7/3/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$1,001.00 ➝ $1,001.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
6/25/2024Truist FinancialReiterated RatingBuy ➝ Buy$892.00 ➝ $1,000.00
6/24/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$994.00 ➝ $1,015.00
6/24/2024Bank of AmericaReiterated RatingBuy ➝ Buy$1,000.00 ➝ $1,000.00
6/24/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
6/17/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
6/11/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
6/7/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$925.00 ➝ $957.00
5/14/2024ArgusBoost TargetBuy ➝ Buy$770.00 ➝ $840.00
5/1/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$900.00 ➝ $1,001.00
5/1/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$850.00 ➝ $900.00
5/1/2024Truist FinancialBoost TargetBuy ➝ Buy$850.00 ➝ $892.00
4/30/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$815.00 ➝ $885.00
4/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$815.00
4/11/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024Erste Group BankUpgradeHold ➝ Buy
4/2/2024CitigroupBoost TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$815.00
3/22/2024Truist FinancialReiterated RatingBuy ➝ Buy$850.00
3/15/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$775.00 ➝ $850.00
3/1/2024Bank of AmericaBoost TargetBuy ➝ Buy$800.00 ➝ $1,000.00
2/21/2024DZ BankDowngradeBuy ➝ Hold$820.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$815.00
2/16/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$805.00 ➝ $950.00
2/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$815.00
2/7/2024Truist FinancialBoost TargetBuy ➝ Buy$650.00 ➝ $850.00
2/7/2024BarclaysBoost TargetOverweight ➝ Overweight$680.00 ➝ $810.00
2/7/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$763.00 ➝ $805.00
2/7/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$710.00 ➝ $865.00
2/6/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$700.00 ➝ $825.00
2/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00
1/24/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$650.00 ➝ $700.00
1/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00
1/23/2024BarclaysBoost TargetOverweight ➝ Overweight$630.00 ➝ $680.00
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
12/19/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$727.00 ➝ $822.00
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
11/29/2023Truist FinancialReiterated RatingBuy ➝ Buy$650.00
11/15/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00
11/9/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$535.00
11/8/2023JPMorgan Chase & Co.Reiterated RatingOverweight
11/3/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$673.00 ➝ $722.00
10/23/2023CitigroupBoost TargetBuy ➝ Buy$525.00 ➝ $675.00
10/23/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00
10/20/2023UBS GroupReiterated RatingBuy ➝ Buy$612.00 ➝ $710.00
10/11/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$640.00 ➝ $673.00
10/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00
10/9/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$615.00 ➝ $650.00
10/6/2023Bank of AmericaBoost Target$600.00 ➝ $700.00
10/2/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00
9/5/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00
9/5/2023ArgusBoost TargetBuy ➝ Buy$470.00 ➝ $620.00
9/5/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$617.00 ➝ $640.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00
8/9/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$560.00 ➝ $617.00
8/9/2023The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$385.00 ➝ $470.00
8/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$550.00
8/9/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$565.00 ➝ $633.00
8/9/2023Truist FinancialBoost TargetBuy ➝ Buy$525.00 ➝ $600.00
8/9/2023BarclaysBoost TargetOverweight ➝ Overweight$500.00 ➝ $590.00
8/9/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$510.00 ➝ $600.00
8/9/2023Credit Suisse GroupBoost TargetOutperform ➝ Outperform$490.00 ➝ $580.00
8/9/2023Bank of AmericaBoost Target$500.00 ➝ $600.00
8/8/2023Jefferies Financial GroupUpgradeHold ➝ Buy$408.00 ➝ $615.00
8/8/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$490.00 ➝ $580.00
8/8/2023Cantor FitzgeraldBoost Target$550.00 ➝ $630.00
8/8/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$500.00 ➝ $615.00
7/28/2023JPMorgan Chase & Co.Boost TargetOverweight$475.00 ➝ $510.00
7/26/2023CitigroupBoost TargetBuy$360.00 ➝ $525.00
7/21/2023Jefferies Financial GroupBoost TargetHold$408.00 ➝ $430.00
7/21/2023Morgan StanleyBoost TargetOverweight$551.00 ➝ $560.00
7/20/2023Truist FinancialBoost TargetBuy$430.00 ➝ $525.00
7/18/2023BMO Capital MarketsBoost Target$505.00 ➝ $565.00
7/14/2023HSBCInitiated CoverageBuy$560.00
6/27/202322nd Century GroupReiterated RatingMaintains
6/27/2023Cantor FitzgeraldBoost Target$485.00 ➝ $550.00
6/27/2023BarclaysBoost Target$420.00 ➝ $500.00
6/20/2023Berenberg BankBoost Target$375.00 ➝ $500.00
5/26/2023Wells Fargo & CompanyBoost Target$440.00 ➝ $500.00
5/24/2023UBS GroupBoost TargetBuy$447.00 ➝ $498.00
5/24/2023Bank of AmericaBoost TargetBuy$450.00 ➝ $500.00
5/15/2023Morgan StanleyBoost Target$478.00 ➝ $507.00
5/4/2023BMO Capital MarketsBoost Target$430.00 ➝ $505.00
5/4/2023JPMorgan Chase & Co.Boost Target$430.00 ➝ $475.00
5/4/2023Credit Suisse GroupBoost Target$420.00 ➝ $490.00
5/1/2023SVB SecuritiesBoost Target$410.00 ➝ $458.00
5/1/2023BarclaysBoost Target$400.00 ➝ $420.00
4/28/20233MReiterated RatingMaintains
4/28/2023Truist FinancialBoost Target$421.00 ➝ $430.00
4/28/2023Cantor FitzgeraldBoost Target$432.00 ➝ $485.00
4/28/2023Credit Suisse GroupBoost Target$400.00 ➝ $420.00
4/28/2023JPMorgan Chase & Co.Boost Target$400.00 ➝ $430.00
4/28/2023UBS GroupBoost Target$438.00 ➝ $447.00
4/28/2023Wells Fargo & CompanyBoost Target$375.00 ➝ $440.00
4/11/2023GuggenheimLower TargetBuy$395.00 ➝ $392.00
4/10/2023Morgan StanleyBoost TargetOverweight$444.00 ➝ $448.00
4/3/2023Jefferies Financial GroupBoost TargetHold$290.00 ➝ $310.00
3/13/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$360.00 ➝ $375.00
3/6/2023Jefferies Financial GroupInitiated CoverageHold$290.00
3/3/2023CitigroupLower TargetBuy$370.00 ➝ $360.00
3/1/2023Morgan StanleyLower TargetOverweight$455.00 ➝ $444.00
2/15/2023Societe GeneraleDowngradeHold ➝ Sell$278.00
2/3/2023Wells Fargo & CompanyLower TargetEqual Weight$375.00 ➝ $360.00
2/3/2023Morgan StanleyBoost TargetOverweight$440.00 ➝ $455.00
1/3/2023BarclaysBoost TargetOverweight$395.00 ➝ $400.00
12/16/2022Leerink PartnersBoost TargetOutperform$384.00 ➝ $410.00
12/15/2022UBS GroupLower TargetBuy$428.00 ➝ $420.00
12/14/2022Morgan StanleyLower TargetOverweight$446.00 ➝ $440.00
12/14/2022JPMorgan Chase & Co.Boost Target$380.00 ➝ $400.00
12/9/2022UBS GroupBoost Target$407.00 ➝ $428.00
12/8/2022Wells Fargo & CompanyBoost TargetEqual Weight$365.00 ➝ $375.00
12/7/2022GuggenheimBoost TargetBuy$399.00 ➝ $401.00
12/6/2022Credit Suisse GroupBoost TargetOutperform$395.00 ➝ $400.00
12/6/2022Morgan StanleyBoost TargetOverweight$436.00 ➝ $446.00
12/5/2022CowenBoost TargetOutperform$390.00 ➝ $430.00
12/5/2022CowenBoost Target$390.00 ➝ $430.00
11/22/2022Berenberg BankBoost TargetBuy$345.00 ➝ $375.00
11/17/2022Credit Suisse GroupInitiated CoverageOutperform$395.00
11/17/2022Morgan StanleyLower TargetOverweight$441.00 ➝ $436.00
11/15/2022Truist FinancialBoost Target$400.00 ➝ $421.00
11/8/2022The Goldman Sachs GroupBoost TargetNeutral$281.00 ➝ $313.00
11/2/2022Leerink PartnersBoost TargetOutperform$341.00 ➝ $384.00
11/2/2022Morgan StanleyBoost TargetOverweight$408.00 ➝ $441.00
11/2/2022Wells Fargo & CompanyBoost TargetEqual Weight$305.00 ➝ $365.00
11/2/2022BarclaysBoost TargetOverweight$355.00 ➝ $395.00
10/12/2022Morgan StanleyLower TargetOverweight$412.00 ➝ $408.00
9/30/2022ArgusBoost Target$315.00 ➝ $360.00
9/22/2022UBS GroupUpgradeNeutral ➝ Buy$335.00 ➝ $363.00
9/7/2022Morgan StanleyBoost TargetOverweight$395.00 ➝ $412.00
9/6/2022BMO Capital MarketsBoost TargetOutperform$369.00 ➝ $396.00
8/25/2022CitigroupBoost Target$285.00 ➝ $370.00
7/27/2022UBS GroupBoost TargetOutperform$335.00
7/8/2022Morgan StanleyBoost TargetOverweight$369.00 ➝ $395.00
7/7/2022BarclaysBoost TargetOverweight$333.00 ➝ $355.00
6/1/2022JPMorgan Chase & Co.Boost Target$340.00 ➝ $355.00
5/23/2022Leerink PartnersInitiated CoverageOutperform$341.00
5/2/2022MizuhoBoost Target$315.00 ➝ $356.00
4/29/2022Morgan StanleyBoost Target$364.00 ➝ $369.00
4/29/2022Wells Fargo & CompanyBoost Target$280.00 ➝ $305.00
4/12/2022The Goldman Sachs GroupBoost TargetNeutral$234.00 ➝ $264.00
4/6/2022Morgan StanleyBoost TargetOverweight$265.00 ➝ $364.00
3/17/2022Bank of AmericaBoost Target$300.00 ➝ $315.00
3/10/2022Daiwa Capital MarketsInitiated CoverageOutperform$286.00
2/4/2022MizuhoLower TargetBuy$302.00 ➝ $293.00
2/4/2022Morgan StanleyLower TargetOverweight$272.00 ➝ $265.00
1/24/2022Morgan StanleyLower TargetOverweight$275.00 ➝ $272.00
1/21/2022DZ BankUpgradeHold ➝ Buy$291.00
1/5/2022MizuhoBoost Target$272.00 ➝ $302.00
1/4/2022Wells Fargo & CompanyBoost TargetEqual Weight$270.00 ➝ $280.00
1/3/2022Sanford C. BernsteinBoost TargetMarket Perform$250.00 ➝ $300.00
12/20/2021Berenberg BankBoost TargetBuy$270.00 ➝ $305.00
12/20/2021BarclaysBoost TargetOverweight$280.00 ➝ $325.00
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$236.00
12/16/2021MizuhoInitiated CoverageBuy$272.00
12/16/2021BMO Capital MarketsBoost TargetOutperform$311.00 ➝ $320.00
12/16/2021Bank of AmericaBoost TargetBuy$285.00 ➝ $300.00
12/16/2021JPMorgan Chase & Co.Reiterated RatingBuy
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$270.00
11/24/2021Truist FinancialBoost TargetBuy$262.00 ➝ $301.00
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$311.00
10/27/2021MizuhoLower TargetBuy$279.00 ➝ $272.00
10/11/2021Berenberg BankUpgradeHold ➝ Buy$240.00 ➝ $270.00
9/29/2021CitigroupUpgradeNeutral ➝ Buy$210.00 ➝ $265.00
9/24/2021JPMorgan Chase & Co.Reiterated RatingBuy$300.00
8/30/2021CowenBoost TargetOutperform$250.00 ➝ $300.00
8/9/2021ArgusBoost TargetBuy$225.00 ➝ $300.00
8/5/2021DZ BankUpgradeHold ➝ Buy$288.00
8/4/2021JPMorgan Chase & Co.Boost TargetTop Pick ➝ Overweight$270.00 ➝ $300.00
8/4/2021Morgan StanleyBoost TargetOverweight$207.00 ➝ $275.00
8/4/2021MizuhoBoost TargetBuy$250.00 ➝ $279.00
7/27/2021Truist FinancialInitiated CoverageBuy$262.00
7/7/2021MizuhoReiterated RatingBuy$250.00
7/6/2021BarclaysBoost TargetOverweight$227.00 ➝ $250.00
7/2/2021Truist FinancialBoost TargetBuy ➝ Buy$225.00 ➝ $262.00
6/24/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$245.00 ➝ $300.00
6/24/2021CowenBoost TargetPositive ➝ Outperform$235.00 ➝ $250.00
6/15/2021JPMorgan Chase & Co.Boost TargetOverweight$240.00 ➝ $260.00
6/14/2021The Goldman Sachs GroupBoost TargetPositive ➝ Conviction-Buy$252.00 ➝ $270.00
6/8/2021Truist FinancialReiterated RatingBuy$225.00
4/28/2021Morgan StanleyLower TargetOverweight$217.00 ➝ $207.00
4/28/2021MizuhoLower TargetBuy$228.00 ➝ $216.00
4/28/2021BarclaysLower TargetOverweight$232.00 ➝ $227.00
3/15/2021Truist FinancialBoost TargetBuy$215.00 ➝ $225.00
2/12/2021CowenBoost TargetOutperform$195.00 ➝ $235.00
2/4/2021Morgan StanleyBoost TargetOverweight$190.00 ➝ $217.00
2/1/2021Truist FinancialBoost Target$200.00 ➝ $215.00
2/1/2021MizuhoBoost TargetBuy$222.00 ➝ $228.00
2/1/2021BarclaysBoost TargetOverweight$190.00 ➝ $232.00
1/22/2021Bank of AmericaBoost TargetBuy$195.00 ➝ $225.00
1/19/2021MizuhoUpgradeNeutral ➝ Buy$164.00 ➝ $222.00
1/12/2021Truist FinancialBoost Target$182.00 ➝ $200.00
12/16/2020MizuhoBoost TargetNeutral$156.00 ➝ $164.00
12/10/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$147.00 ➝ $183.00
11/17/2020MizuhoLower TargetNeutral$164.00 ➝ $156.00
11/10/2020Sanford C. BernsteinInitiated CoverageMarket Perform$150.00
10/28/2020Morgan StanleyLower TargetOverweight$176.00 ➝ $170.00
10/23/2020Truist FinancialInitiated CoverageBuy$180.00
10/16/2020JPMorgan Chase & Co.Boost TargetOverweight$190.00 ➝ $200.00
9/29/2020Berenberg BankInitiated CoverageHold$144.00
9/3/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$149.55 ➝ $176.00
8/14/2020Morgan StanleyBoost TargetEqual Weight$148.00 ➝ $157.00
6/29/2020MizuhoBoost TargetNeutral$155.00 ➝ $164.00
6/19/2020Bank of AmericaReiterated RatingBuy$180.00
6/17/2020JPMorgan Chase & Co.Boost TargetOverweight$175.00 ➝ $190.00
6/16/2020GuggenheimUpgradeNeutral ➝ Buy$182.00
4/24/2020MizuhoBoost TargetBuy$148.00 ➝ $155.00
4/24/2020CfraBoost TargetHold$146.00 ➝ $167.00
4/24/2020Cantor FitzgeraldBoost TargetOverweight$156.00 ➝ $185.00
4/20/2020UBS GroupDowngradeBuy ➝ Neutral$157.00 ➝ $158.00
4/19/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
4/15/2020CowenBoost TargetOutperform$145.00 ➝ $160.00
4/9/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$148.00
4/2/2020MizuhoReiterated RatingHold$148.00
4/2/2020Morgan StanleyLower TargetOverweight ➝ Equal Weight$150.00 ➝ $148.00
3/11/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$168.00
2/27/2020BarclaysInitiated CoverageOverweight
2/18/2020Cantor FitzgeraldReiterated RatingBuy$156.00
2/5/2020MizuhoInitiated CoverageNeutral$148.00
2/3/2020Cantor FitzgeraldReiterated RatingBuy$156.00
12/30/2019ArgusBoost TargetBuy$145.00 ➝ $165.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.11 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 108 very positive mentions
  • 88 positive mentions
  • 14 negative mentions
  • 4 very negative mentions
Mentions as of
5/24/2024
  • 98 very positive mentions
  • 63 positive mentions
  • 12 negative mentions
  • 2 very negative mentions
Mentions as of
6/23/2024
  • 99 very positive mentions
  • 51 positive mentions
  • 13 negative mentions
  • 3 very negative mentions
Mentions as of
7/23/2024
  • 98 very positive mentions
  • 90 positive mentions
  • 14 negative mentions
  • 1 very negative mentions
Mentions as of
8/22/2024
  • 83 very positive mentions
  • 73 positive mentions
  • 16 negative mentions
  • 4 very negative mentions
Mentions as of
9/21/2024
  • 74 very positive mentions
  • 67 positive mentions
  • 11 negative mentions
  • 4 very negative mentions
Mentions as of
10/21/2024
  • 171 very positive mentions
  • 99 positive mentions
  • 29 negative mentions
  • 6 very negative mentions
Mentions as of
11/20/2024
  • 272 very positive mentions
  • 97 positive mentions
  • 12 negative mentions
  • 5 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 272 very positive mentions
  • 97 positive mentions
  • 12 negative mentions
  • 5 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $767.76
Low: $766.61
High: $811.35

50 Day Range

MA: $818.94
Low: $727.57
High: $931.16

52 Week Range

Now: $767.76
Low: $567.02
High: $972.53

Volume

9,497,292 shs

Average Volume

3,238,733 shs

Market Capitalization

$728.85 billion

P/E Ratio

83.00

Dividend Yield

0.67%

Beta

0.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Eli Lilly and Company?

The following sell-side analysts have issued reports on Eli Lilly and Company in the last twelve months: Argus, Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Deutsche Bank Aktiengesellschaft, DZ Bank AG, Erste Group Bank AG, Evercore ISI, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Redburn Atlantic, Sanford C. Bernstein, The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for LLY.

What is the current price target for Eli Lilly and Company?

0 Wall Street analysts have set twelve-month price targets for Eli Lilly and Company in the last year. Their average twelve-month price target is $1,002.22, suggesting a possible upside of 30.5%. Citigroup Inc. has the highest price target set, predicting LLY will reach $1,250.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $723.00 for Eli Lilly and Company in the next year.
View the latest price targets for LLY.

What is the current consensus analyst rating for Eli Lilly and Company?

Eli Lilly and Company currently has 4 hold ratings and 17 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LLY.

What other companies compete with Eli Lilly and Company?

Other companies that are similar to Eli Lilly and Company include Johnson & Johnson, AbbVie, Merck & Co., Inc., Pfizer and Bristol-Myers Squibb. Learn More about companies similar to Eli Lilly and Company.

How do I contact Eli Lilly and Company's investor relations team?

Eli Lilly and Company's physical mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company's listed phone number is (317) 276-2000 and its investor relations email address is [email protected]. The official website for Eli Lilly and Company is www.lilly.com. Learn More about contacing Eli Lilly and Company investor relations.